Atherogenesis and its relationship to coronary risk factors

Clinical Cornerstone

Volumn 1, Issue 1, 1998, Pages 3-14

  LaRosa, John C ^a  

^a TULANE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; HUMAN; REVIEW; RISK FACTOR;

ARTERIOSCLEROSIS; CORONARY DISEASE; HUMANS; RISK FACTORS;

EID: 0032081382     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1098-3597(98)90003-5     Document Type: Article

References (23)

1. Selwyn AP, Kinlay S, Creager M, et al. Cell dysfunction in atherosclerosis and the ischemic manifestations of coronary artery disease. Am J Cardiol. 1997;79:17-23.
2. Consigny PM. Pathogenesis of atherosclerosis. Advances in clinical medicine. Am J Roentgenol. 1995;164:553-558.
3. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
4. Wissler RW. Important points in the pathogenesis of atherosclerosis. In: Gotto AM, ed. Atherosclerosis. Kalamazoo, Mich: The Upjohn Company; 1992.
5. Gupta S, Leatham EW, Carrington D, et al. Elevated chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404-407.
6. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. NEJM. 1997; 336:973-979.
7. Aviram M. Oxidative modification of low density lipoprotein and its relation to atherosclerosis, Isr J Med Sci. 1995;31:241-249.
8. Hill SA, McQueen MJ. Reverse cholesterol transport - a review of the process and its clinical implications. Clin Biochem. 1997;30:517-525.
9. Mackness MI, Arrol S, Mackness B, Durrington PN. Alloenzymes of paraoxanase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet. 1997;349:851-852.
10. LaRosa JC. Diet and cardiovascular disease. Prev Cardiol. 1998;1:40-45.
11. Glasser SP, Selwyn AP, Ganz P. Atherosclerosis: risk factors and the vascular endothelium. Am Heart J. 1996;131:379-384.
12. Hopkins PN, Wu LL, Wu J, et al. Higher plasma homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 1995;15:1314-1320.
13. Alexander RW. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension. 1995;25:155-161.
14. Ruderman NB, Schneider SH. Diabetes, exercise, and atherosclerosis. Diabetes Care. 1992;15(suppl 4):1787-1793.
15. Roberts WC. Preventing and arresting coronary atherosclerosis. Am Heart J. 1995;130:580-600.
16. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. NEJM. 1995;332:481-487.
17. Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. NEJM. 1995;332:488-493.
18. Plotnick GD, Corretti MC, Robert VA. Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. JAMA. 1997; 278:1682-1686.
19. Bilato C, Crow MT. Atherosclerosis and the vascular biology of aging. Aging Clin Exp Res. 1996;8:221-234.
20. LaRosa JC. The pharmacology and effectiveness of specific lipid-active drugs: estrogen/sex steroids. Coron Artery Dis. 1996;7:683-688.
21. Vlassara H. Advanced glycation end-products and atherosclerosis. Ann Med. 1996;28:419-426.
22. LaRosa JC, ed. Medical Management of Atherosclerosis. New York, NY: Marcel Dekker; 1998.
23. Gurfinkel E, Bozovich G, Daroca A, et al, for the ROXIS Study Group. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet. 1997;350:404-407.